CHAMP clinical trial examines efficacy of NVK002 in controlling pediatric myopia

Focus of trial is to determine medication's safety, efficacy for treating myopia progression By Lynda Charters; Reviewed by Rupa K. Wong, MD, PAAR Findings from the CHAMP phase 3 study (NCT03350620) show that NVK002 atropine 0.01% (Vyluma, Inc) "meaningfully slowed" myopia progression...

Full description

Saved in:
Bibliographic Details
Published inOphthalmology Times Vol. 49; no. 7; p. 13
Main Author Wong, Rupa K
Format Trade Publication Article
LanguageEnglish
Published Monmouth Junction MultiMedia Healthcare Inc 01.07.2024
Subjects
Clinical trials
Drug dosages
Good Manufacturing Practice
Myopia
Ophthalmology
Pediatrics
Strabismus
United States > US
Texas
Online AccessGet full text

Cover

More Information
Summary:Focus of trial is to determine medication's safety, efficacy for treating myopia progression By Lynda Charters; Reviewed by Rupa K. Wong, MD, PAAR Findings from the CHAMP phase 3 study (NCT03350620) show that NVK002 atropine 0.01% (Vyluma, Inc) "meaningfully slowed" myopia progression in pediatric patients with myopia over a 36-month period,1 according to Rupa K. Wong, MD, FAAP. The study participants were aged 3 to 16 years and had a spherical equivalent refractive error (SER) ranging from -0.5 to -6 D in each eye, low astigmatism, and distance vision that was correctable to at least 20/25 visual acuity in each eye. Age effect on treatment responses to 0.05%, 0.025%, and 0.01 % atropine: low-concentration atropine for myopia progression study.
ISSN:0193-032X
2150-7333